HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.

AuthorsNikolaos Patsinakidis, Alexander Kreuter, Rose K C Moritz, Markus Stücker, Peter Altmeyer, Katrin Möllenhoff
JournalActa dermato-venereologica (Acta Derm Venereol) Vol. 95 Issue 2 Pg. 233-4 (Feb 2015) ISSN: 1651-2057 [Electronic] Sweden
PMID24733422 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin
Topics
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor (analysis)
  • Biopsy
  • Brentuximab Vedotin
  • Humans
  • Immunoconjugates (therapeutic use)
  • Immunohistochemistry
  • Ki-1 Antigen (analysis)
  • Lymphoma, Large-Cell, Anaplastic (drug therapy, immunology, pathology)
  • Male
  • Middle Aged
  • Remission Induction
  • Skin Neoplasms (drug therapy, immunology, pathology)
  • Skin Ulcer (drug therapy, immunology, pathology)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: